Finally, a perspective randomized phase III study in un-resectable lung stage III cancer patients aimed to receive chemoradiation followed by Durvalumab or placebo for 12 months (PACIFIC) reported a significant advantage in PFS in the experimental arm, which was unrelated to PDL-1 expression in the tumor (25). The gene discussed is CD274; the disease is cancer.